The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Paves way for CNS cancer test rollout
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
Subscribe To Our Newsletter & Stay Updated
